Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 12 Jun 2025 | Marie-Hélène Pradines Head of Unit | Small midcaps recommendation | — |
| 12 Jun 2025 | Marie-Hélène Pradines Head of Unit | Small midcaps recommendation | SRC |
| 03 Jun 2025 | Florika Fink-Hooijer Director-General | Discussion in the margins of HERA Industry days | — |
| 03 Jun 2025 | Florika Fink-Hooijer Director-General | Discussion in the margins of HERA Industry days | SRC |
| 31 Mar 2025 | Felice Zaccheo Head of Unit | Exchange of views on bi-regional cooperation and private sector investment in strengthening LAC’s health sector self-sufficiency, regulatory harmonisation, regional tech transfers and manufacturing in Latin America. | — |
| 31 Mar 2025 | Felice Zaccheo Head of Unit | Exchange of views on bi-regional cooperation and private sector investment in strengthening LAC’s health sector self-sufficiency, regulatory harmonisation, regional tech transfers and manufacturing in Latin America. | SRC |
| 25 Mar 2025 | Ann-Sofie Ronnlund Cabinet member | Microsoft Teams Meeting- life sciences research and innovation | — |
| 25 Mar 2025 | Ann-Sofie Ronnlund Cabinet member | Microsoft Teams Meeting- life sciences research and innovation | SRC |
| 13 Mar 2023 | Pierre Delsaux Director-General | Valneva updated HERA on their products available and in development. | — |
| 13 Mar 2023 | Pierre Delsaux Director-General | Valneva updated HERA on their products available and in development. | SRC |
| 02 Mar 2021 | Thierry Breton Commissioner | Vaccine production | — |
| 02 Mar 2021 | Thierry Breton Commissioner | Vaccine production | SRC |
Mission & Goals
Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. The Company has several vaccines in development including vaccines against Lyme disease and Zika. Valneva’s portfolio includes three commercial vaccines for travelers: IXCHIQ® for the prevention of disease caused by chikungunya virus (CHIKV), IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC.
EU Legislative Interests
Given Valneva’s experience in emerging diseases, the company’s is engaging with MEPs, Commission (e.g., DG HERA, DG ECHO, DG GROW, DG RTD), European Council and Permanent Representations on policies related to public health, and (funding for) research and innovation. More specifically: Horizon Europe (Horizon 2020), EU4Health, Cross Border Health Threats Regulation, General Pharmaceutical Legislation, Pharmaceutical / Life Sciences Strategy, New Industrial Strategy for Europe, European Critical Medicines Alliance, Union Civil Protection Mechanism, EU Preparedness Union, including medical countermeasure and stockpiling strategies, EU FAB, Biotech Act, Critical Medicines Act.
Communication Activities
Starting shot for vaccines. Early lessons from the ups and downs of COVID-19 immunisation roll-out(s) - in cooperation with European Health Forum Gastein (2021) "Outbreak Diseases: a sudden risk, a constant threat” - Event in the European Parliament to address preparedness for outbreak diseases (2023). Nov 2024 Event held at the Austrian Permanent Representation to the EU "How can the EU support national industry to address global crises and support a 'Preparedness Union?'", focussing in particular on climate-related disease outbreaks, promoting biotech innovation, enhancing health preparedness and aligning industrial and health policies.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Vaccines Europe France Biotech Pharmig - Verband der pharmazeutischen Industrie Österreichs ÖVIH - Österreichischer Verband der Impfstoffhersteller WKÖ - Austrian Federal Economic Chamber Industriellenvereinigung (Vereinigung der Österreichischen Industrie) Biotech Austria Signatary of UN Global Compact LIF - Läkemedelsindustriföreningens LEEM - Les Entreprises du Médicament ABPI UK - The Association of the British Pharmaceutical Industry Royal Society of Biology (UK) Biotechnology Innovation Organization (BIO, USA) Adult Vaccine Access Coalition (AVAC, USA)
Organisation Members
n/a
Additional Information
In July 2024, we have received a grant of up to $41.3 million from CEPI, for which €38 million have been mobilised under Horizon Europe. This indirect grant is not shown above.